Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2023-02-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of guarantees for its controlling subsidiaries. It lists specific guarantee amounts, counterparties, contract details, and cumulative guarantee exposure. The content focuses on financial guarantees provided to subsidiaries for credit facilities and financing, including contract terms and guarantee scope. There is no indication that this is a full financial report, audit report, earnings release, or management discussion. It is not a regulatory certification or a brief announcement of a report publication. The document is a formal announcement about financing-related guarantees, which fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company to support subsidiaries' credit lines.
2023-02-21 Chinese
关于股东部分股份解押及质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the partial release and new pledging of shares by a major shareholder (the controlling shareholder) of the company. It details the number of shares pledged and released, the pledgee institutions, and the purpose of the pledges (financing credit enhancement). It also includes information about the controlling shareholder's financial status and confirms no adverse impact on the company. There are no financial statements, no management discussion or analysis, no earnings data, and no regulatory certifications. The document is a formal disclosure of share pledge and release activities, which is a capital structure update related to share pledging. This fits the category of Capital/Financing Update (CAP). The document length is 3534 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2023-02-16 Chinese
关于筹划重大事项的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress of planning a major transaction, specifically a major asset restructuring and mixed-ownership reform. It mentions ongoing negotiations, audit and evaluation work, and that no formal agreement has been signed yet. The document repeatedly emphasizes risk warnings and the need for further approvals and disclosures. The text is relatively short (1585 characters) and does not contain actual financial statements or detailed financial data. It is an update on the progress of a significant corporate event rather than the event's completion or a detailed report. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including progress announcements on major transactions.
2023-01-30 Chinese
2022年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast (业绩预告) issued by Shenzhen Haiwang Bioengineering Co., Ltd. It provides preliminary estimated financial results for the full year 2022, including expected net profit/loss, earnings per share, and revenue figures. It explicitly states that the data is preliminary, unaudited, and subject to final confirmation in the full annual report. The document also discusses reasons for performance changes and risks, but does not contain audited financial statements or comprehensive financial analysis. The document length is short (1788 characters) and it serves as an earnings forecast rather than a full earnings release or annual report. According to the filing definitions, an earnings forecast or performance guidance document is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results or key highlights. Therefore, the appropriate classification is ER with high confidence. FY 2022
2023-01-30 Chinese
关于为全资子公司提供担保实施情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the provision of guarantees by the company for its wholly-owned subsidiaries. It details the guarantee amounts, contractual terms, and cumulative guarantee exposure. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about a specific corporate action (providing guarantees) rather than a financial report or meeting material. It is not a full annual or interim report, nor a call transcript or capital update. The content fits best under Regulatory Filings (RNS) as it is a compliance disclosure about guarantees provided by the company.
2023-01-18 Chinese
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the implementation of guarantees provided to its controlling subsidiaries. It lists multiple guarantee contracts with banks and financial institutions, specifying amounts, terms, and conditions. The document is an official company announcement about guarantees related to financing activities, not a financial report or audit. It does not contain financial statements or earnings data, nor is it a meeting presentation or voting result. The content fits best under Capital/Financing Update (CAP) as it relates to guarantees supporting financing and credit facilities for subsidiaries.
2023-01-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.